Maryland is currently home to 2689 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone fo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2025
Locations: Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase, Maryland
Conditions: Ulcerative Colitis
SUBLOCADE Long-term Outcomes
Recruiting
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Maryland Treatment Centers, Baltimore, Maryland
Conditions: Opioid Use Disorder
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Long-term Observation of Participants With Mood Disorders
Recruiting
Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk. Researchers want to follow up with this group to see if they continue to have mental health symptoms and receive psychiatric treatments. Objective: To learn the long-term impact of depression, bipolar disorder, and sui... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression, Suicide Risk
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
Recruiting
Background: Researchers developed \[11C\]MC1, a radioligand for cyclooxygenase-2 (COX-2). COX-2 is an enzyme induced in the brain during inflammation. Researchers want to see the levels of COX-1 (measured as distribution volume VT) are elevated in the brain of two groups of mood disorders patients undergoing MDE relative to the control group. Objective: To determine whether COX-1 and COX-2 are detectable in the brains of individuals with MDD experiencing a major depressive episode (MDE). Eli... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: University of Maryland Shore Medical Center at Easton, Easton, Maryland
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Recruiting
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.
Gender:
ALL
Ages:
48 hours and below
Trial Updated:
04/03/2025
Locations: 5092, Johns Hopkins Clinical Research Site, Baltimore, Maryland
Conditions: HIV Infection
Drug-Drug Interaction Potential of Mavorixafor
Recruiting
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Parexel International LLC, Baltimore, Maryland
Conditions: Healthy Participants
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Recruiting
The study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), a psychotherapeutic crisis intervention treatment for suicidal adolescents that teaches youth skills to prevent suicidal crises an... Read More
Gender:
ALL
Ages:
Between 12 years and 19 years
Trial Updated:
04/02/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Supporting Parents in Affirming Their Children's Experiences of Stigma
Recruiting
The purpose of this study is to develop and test two brief online writing interventions to improve parental acceptance of sexual and gender minority youth (SGMY) in the Southeast United States.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/02/2025
Locations: University of Maryland, College Park, Maryland
Conditions: Parent-Child Relations
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Recruiting
Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells called CD4 T cells. The low CD4 T cells renders people with ICL prone to many types of severe infections, autoimmune diseases, and cancers. Although these infections and diseases can be treated whenever occur, there is currently no treatment that targeting the underlying deficiency of CD4 T cells can provide a definitive treatment for people with ICL. Objective: To test a new drug (N... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Idiopathic CD4 Lymphopenia
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
Recruiting
Background: Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD. Objective: To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated do... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
04/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Granulomatous Disease, CGD